Literature DB >> 17875649

Mechanism by which exosites promote the inhibition of blood coagulation proteases by heparin-activated antithrombin.

Gonzalo Izaguirre1, Richard Swanson1, Srikumar M Raja1, Alireza R Rezaie2, Steven T Olson1.   

Abstract

Heparin activates the serpin, antithrombin, to inhibit its target blood-clotting proteases by generating new protease interaction exosites. To resolve the effects of these exosites on the initial Michaelis docking step and the subsequent acylation and conformational change steps of antithrombin-protease reactions, we compared the reactions of catalytically inactive S195A and active proteases with site-specific fluorophore-labeled antithrombins that allow monitoring of these reaction steps. Heparin bound to N,N'-dimethyl-N-(acetyl)-N'-(7-nitrobenz-3-oxa-1,3-diazol-4-yl)ethylenediamine (NBD)-fluorophore-labeled antithrombins and accelerated the reactions of the labeled inhibitor with thrombin and factor Xa similar to wild type. Equilibrium binding of NBD-labeled antithrombins to S195A proteases showed that exosites generated by conformationally activating antithrombin with a heparin pentasaccharide enhanced the affinity of the serpin for S195A factor Xa minimally 100-fold. Moreover, additional bridging exosites provided by a hexadecasaccharide heparin activator enhanced antithrombin affinity for both S195A factor Xa and thrombin at least 1000-fold. Rapid kinetic studies showed that these exosite-mediated enhancements in Michaelis complex affinity resulted from increases in k(on) and decreases in k(off) and caused antithrombin-protease reactions to become diffusion-controlled. Competitive binding and kinetic studies with exosite mutant antithrombins showed that Tyr-253 was a critical mediator of exosite interactions with S195A factor Xa; that Glu-255, Glu-237, and Arg-399 made more modest contributions to these interactions; and that exosite interactions reduced k(off) for the Michaelis complex interaction. Together these results show that exosites generated by heparin activation of antithrombin function both to promote the formation of an initial antithrombin-protease Michaelis complex and to favor the subsequent acylation of this complex.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875649     DOI: 10.1074/jbc.M702462200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa.

Authors:  Steven T Olson; Richard Swanson; Maurice Petitou
Journal:  Blood       Date:  2011-12-05       Impact factor: 22.113

2.  Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin.

Authors:  Benjamin Richard; Richard Swanson; Sophia Schedin-Weiss; Ben Ramirez; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2008-03-28       Impact factor: 5.157

3.  Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.

Authors:  Wei Li; Ty E Adams; Jyoti Nangalia; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

4.  Meizothrombin is an unexpectedly zymogen-like variant of thrombin.

Authors:  Harlan N Bradford; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

Review 5.  Inhibitory serpins. New insights into their folding, polymerization, regulation and clearance.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  Biochem J       Date:  2016-08-01       Impact factor: 3.857

6.  Kinetic intermediates en route to the final serpin-protease complex: studies of complexes of α1-protease inhibitor with trypsin.

Authors:  Ashoka A Maddur; Richard Swanson; Gonzalo Izaguirre; Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

7.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Authors:  Genmin Lu; Francis R DeGuzman; Stanley J Hollenbach; Mark J Karbarz; Keith Abe; Gail Lee; Peng Luan; Athiwat Hutchaleelaha; Mayuko Inagaki; Pamela B Conley; David R Phillips; Uma Sinha
Journal:  Nat Med       Date:  2013-03-03       Impact factor: 53.440

8.  Kinetic characterization of the protein Z-dependent protease inhibitor reaction with blood coagulation factor Xa.

Authors:  Xin Huang; Richard Swanson; George J Broze; Steven T Olson
Journal:  J Biol Chem       Date:  2008-09-03       Impact factor: 5.157

Review 9.  Exosite determinants of serpin specificity.

Authors:  Peter G W Gettins; Steven T Olson
Journal:  J Biol Chem       Date:  2009-04-28       Impact factor: 5.157

10.  Engineering functional antithrombin exosites in alpha1-proteinase inhibitor that specifically promote the inhibition of factor Xa and factor IXa.

Authors:  Gonzalo Izaguirre; Alireza R Rezaie; Steven T Olson
Journal:  J Biol Chem       Date:  2008-11-14       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.